Cambridge Cognition

Cambridge Cognition develops digital assessment technologies and clinical trial platforms for central nervous system (CNS) research and drug development. Backed by over 30 years of scientific discovery and validation, the company serves leading pharmaceutical organisations, research institutions, and healthcare professionals worldwide. Its tools are designed for use both in-clinic and remotely, supporting decentralised study designs and an improved patient experience.

The company's team includes neuroscientists, data specialists, consultants, and project managers who assist clients in designing and delivering studies across a broad range of neurological and psychiatric indications. Cambridge Cognition's digital cognitive assessments have been validated in over 3,000 peer-reviewed publications and applied across more than 250 indications, with over one million patients assessed using its digital health tools.

Core Technologies

• Touchscreen cognitive assessments (CANTAB®): Scientifically validated digital cognitive assessments designed to deliver highly sensitive and accurate results across a wide range of cognitive domains.
• Voice analysis: Automated scoring of verbal cognitive assessments using speech analysis technologies, including applications as objective biomarkers in conditions such as major depressive disorder (MDD) and Alzheimer's disease.
• Electronic questionnaires and scales (eCOA): Digital administration of both established and bespoke questionnaires and clinical outcome assessments.
• High frequency testing: Short, accessible cognitive tasks deployed at regular intervals throughout the day to capture day-to-day fluctuations in cognitive function.
• Decentralised clinical trials platform: End-to-end study management covering the full trial lifecycle from site to patient, including recruitment, data collection, and reporting.
• Ratings quality assurance (AQUA): Scale review services providing rater training, central monitoring, scale management, and speaker verification to ensure high-quality data and improve trial outcomes.

Therapeutic Areas

• Alzheimer's disease
• ADHD
• Autism spectrum disorder
• Cognitive safety
• Core cognitive function
• Depression
• Down's syndrome
• Drug abuse liability
• Epilepsy
• Huntington's disease
• Multiple sclerosis
• Neuromuscular disorders
• Obsessive compulsive disorder
• Parkinson's disease
• Schizophrenia
• Stroke and cerebrovascular disease
• Traumatic brain injury

Cognitive Domains Assessed

• Attention and psychomotor speed
• Emotion and social cognition
• Executive function
• Memory

Services for Drug Development and Research

• Study design: Consultancy and support for designing CNS clinical trials and research studies.
• Patient experience: Technologies and approaches aimed at improving participant engagement and accessibility, including decentralised and remote assessment options.
• Study management and support: Ongoing operational support throughout the trial lifecycle.
• Data management and reporting: Handling and analysis of study data with reporting capabilities.
• Statistical consultancy: Available for academic research clients alongside technology delivery and support services.
• Technologies for healthcare: Tools available for clinical use by healthcare professionals.

Cambridge Cognition serves both the drug development and academic research sectors, as well as clinicians requiring cognitive assessment tools in healthcare settings. The CANTAB platform supports web-based testing and has been applied across a broad spectrum of neurological, psychiatric, and neurodevelopmental conditions.